By performing targeted lipidomics in 49 patients of the ATTIRE trial, the same group of investigators also explored the potentiality of human serum albumin infusions to restore immune function in patients with AD cirrhosis and ACLF, the effects of albumin on PGE2 binding and its potential interaction with proresolving lipid mediators [54]. The gene discussed is ALB; the disease is Alzheimer disease.